| ILLUMINA INC. DL-,01 |
| USA |
| Gesundheit |
| US4523271090 / 927079 |
| ILU (Frankfurt) / ILMN (NASDAQ) |
| FRA:ILU, ETR:ILU, ILU:GR, NASDAQ:ILMN |
| S&P500 |
| http://www.illumina.com/ |
|
Illumina, Inc. is a life sciences and diagnostics company that develops, manufactures, and markets tools and integrated systems for the analysis of genetic material. Its primary focus is on next-generation sequencing technologies, providing high-thro..
>Volltext.. |
| 27568.32 Mio. EUR |
| 28758.08 Mio. EUR |
| 3848.52 Mio. EUR |
| 998.3 Mio. EUR |
| 706.35 Mio. EUR |
| 4.63 EUR |
| 2163.56 Mio. EUR |
| 890.43 Mio. EUR |
| 937.52 Mio. EUR |
| 0.74 |
| 8.28% |
| -32.36% |
| - |
| - |
| - |
| 3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 251.748.434 Euro. |
| ILLUMINA |
| 22.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|